Neutrophil-to-lymphocyte ratio at diagnosis as a biomarker for survival of amyotrophic lateral sclerosis

References

• Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377:162–72.
   PubMed Web of Science ®Google Scholar
• van Es MAMD, Hardiman OP, Chio AP, Al-Chalabi AP, Pasterkamp RJP, Veldink JHP, et al. Amyotrophic lateral sclerosis. Lancet. 2017;390:2084–98.
   PubMed Web of Science ®Google Scholar
• McCombe PA, Garton FC, Katz M, Wray NR, Henderson RD. What do we know about the variability in survival of patients with amyotrophic lateral sclerosis? Expert Rev Neurother. 2020;20:921–41.
   PubMed Web of Science ®Google Scholar
• Drory VE, Artmonov I. Earlier onset and shorter survival of amyotrophic lateral sclerosis in Jewish patients of North African origin A clue to modifying genetic factors? J Neurol Sci. 2007;258:39–43.
   PubMed Web of Science ®Google Scholar
• Baumann F, Henderson RD, Morrison SC, Brown M, Hutchinson N, Douglas JA, et al. Use of respiratory function tests to predict survival in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010;11:194–202.
   PubMed Web of Science ®Google Scholar
• Nona RJ, Xu Z, Robinson GA, Henderson RD, McCombe PA. Age of onset and length of survival of Queensland patients with amyotrophic lateral sclerosis: with details of subjects with early onset and subjects with long survival. Neurodegener Dis. 2022;22:104–21.
   PubMed Web of Science ®Google Scholar
• Rong P, Yunusova Y, Wang J, Green JR. Predicting early bulbar decline in amyotrophic lateral sclerosis: a speech subsystem approach. Behav Neurol. 2015;2015:183027–11.
   PubMed Web of Science ®Google Scholar
• Gordon PH, Cheng B, Katz IB, Mitsumoto H, Rowland LP. Clinical features that distinguish PLS, upper motor neuron―dominant ALS, and typical ALS. Neurology 2009;72:1948–52.
   PubMed Web of Science ®Google Scholar
• Rafiq MK, Lee E, Bradburn M, McDermott CJ, Shaw PJ. Creatine kinase enzyme level correlates positively with serum creatinine and lean body mass, and is a prognostic factor for survival in amyotrophic lateral sclerosis. Eur J Neurol. 2016;23:1071–8.
   PubMed Web of Science ®Google Scholar
• Turner MR, Parton MJ, Shaw CE, Leigh PN, Al-Chalabi A. Prolonged survival in motor neuron disease: a descriptive study of the King’s database 1990–2002. J Neurol Neurosurg Psychiatry. 2003;74:995–7.
   PubMed Web of Science ®Google Scholar
• Zoccolella S, Beghi E, Palagano G, Fraddosio A, Samarelli V, Lamberti P, et al. Predictors of delay in the diagnosis and clinical trial entry of amyotrophic lateral sclerosis patients: a population-based study. J Neurol Sci. 2006;250:45–9.
   PubMed Web of Science ®Google Scholar
• Shaabi A. Modeling amyotrophic lateral sclerosis progression: logic in the logit. Cureus 2022;14:e24887.
   PubMed Web of Science ®Google Scholar
• Westeneng H-J, Debray TPA, Visser AE, van Eijk RPA, Rooney JPK, Calvo A, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 2018;17:423–33.
   PubMed Web of Science ®Google Scholar
• Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci. 1999;169:13–21.
   PubMed Web of Science ®Google Scholar
• Fang T, Al Khleifat A, Stahl DR, Lazo La Torre C, Murphy C, Uk-Mnd Lical S, et al. Comparison of the King’s and MiToS staging systems for ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:227–32.
   PubMed Web of Science ®Google Scholar
• Benatar M, Boylan K, Jeromin A, Rutkove SB, Berry J, Atassi N, et al. ALS biomarkers for therapy development: State of the field and future directions. Muscle Nerve. 2016;53:169–82.
   PubMed Web of Science ®Google Scholar
• Huynh W, Dharmadasa T, Vucic S, Kiernan MC. Functional biomarkers for amyotrophic lateral sclerosis. Front Neurol. 2018;9:1141.
   PubMed Web of Science ®Google Scholar
• Kirk SE, Tracey TJ, Steyn FJ, Ngo ST. Biomarkers of metabolism in amyotrophic lateral sclerosis. Front Neurol. 2019;10:191.
   PubMed Web of Science ®Google Scholar
• Meyer T, Schumann P, Weydt P, Petri S, Koc Y, Spittel S, et al. Neurofilament light‐chain response during therapy with antisense oligonucleotide tofersen in SOD1‐related ALS: treatment experience in clinical practice. Muscle Nerve. 2023;67:515–21.
   PubMed Web of Science ®Google Scholar
• Xu Z, Henderson RD, David M, McCombe PA. Neurofilaments as biomarkers for amyotrophic lateral sclerosis: a systematic review and meta-analysis. PLoS One. 2016;11:e0164625-e.
   Web of Science ®Google Scholar
• Beers DR, Thonhoff JR, Faridar A, Thome AD, Zhao W, Wen S, et al. Tregs attenuate peripheral oxidative stress and acute phase proteins in ALS. Ann Neurol. 2022;92:195–200.
   PubMed Web of Science ®Google Scholar
• Kondĕlková K, Vokurková D, Krejsek J, Borská L, Fiala Z, Ctirad A. Regulatory T cells (TREG) and their roles in immune system with respect to immunopathological disorders. Acta Medica (Hradec Kralove). 2010;53:73–7.
   PubMedGoogle Scholar
• Dong C-H, Wang Z-M, Chen S-Y. Neutrophil to lymphocyte ratio predict mortality and major adverse cardiac events in acute coronary syndrome: a systematic review and meta-analysis. Clin Biochem. 2018;52:131–6.
   PubMed Web of Science ®Google Scholar
• Keizman D, Rogowski O, Berliner S, Ish-Shalom M, Maimon N, Nefussy B, et al. Low-grade systemic inflammation in patients with amyotrophic lateral sclerosis. Acta Neurol Scand. 2009;119:383–9.
   PubMed Web of Science ®Google Scholar
• Lagunas‐Rangel FA. Neutrophil‐to‐lymphocyte ratio and lymphocyte‐to‐C‐reactive protein ratio in patients with severe coronavirus disease 2019 (COVID‐19): a meta‐analysis. J Med Virol. 2020;92:1733–4.
   PubMed Web of Science ®Google Scholar
• Choi SJ, Hong YH, Kim SM, Shin JY, Suh YJ, Sung JJ. High neutrophil-to-lymphocyte ratio predicts short survival duration in amyotrophic lateral sclerosis. Sci Rep. 2020;10:428.
   PubMed Web of Science ®Google Scholar
• Cotet C, Alarcan H, Hérault O, Corcia P, Vourc’h P, Andres CR, et al. Neutrophil to lymphocyte ratio as a prognostic marker in amyotrophic lateral sclerosis. Biomolecules 2023;13:1689.
   PubMed Web of Science ®Google Scholar
• Leone MA, Mandrioli J, Russo S, Cucovici A, Gianferrari G, Lisnic V, et al. Neutrophils-to-lymphocyte ratio is associated with progression and overall survival in amyotrophic lateral sclerosis. Biomedicines 2022;10:354.
   PubMed Web of Science ®Google Scholar
• Wei QQ, Hou YB, Zhang LY, Ou RW, Cao B, Chen YP, et al. Neutrophil-to-lymphocyte ratio in sporadic amyotrophic lateral sclerosis. Neural Regen Res. 2022;17:875–80.
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10:89.
   PubMed Web of Science ®Google Scholar
• Whiting P, Rutjes AWS, Reitsma JB, Bossuyt PMM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003;3:25.
   PubMedGoogle Scholar
• Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293–9.
   PubMed Web of Science ®Google Scholar
• de Carvalho M, Dengler R, Eisen A, England JD, Kaji R, Kimura J, et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol. 2008;119:497–503.
   PubMed Web of Science ®Google Scholar
• Shefner JM, Al-Chalabi A, Baker MR, Cui LY, de Carvalho M, Eisen A, et al. A proposal for new diagnostic criteria for ALS. Clin Neurophysiol. 2020;131:1975–8.
   PubMed Web of Science ®Google Scholar
• Murdock BJ, Goutman SA, Boss J, Kim S, Feldman EL. Amyotrophic lateral sclerosis survival associates with neutrophils in a sex-specific manner. Neurol Neuroimmunol Neuroinflamm 2021;8:e953.
   PubMed Web of Science ®Google Scholar
• Clark TG, Bradburn MJ, Love SB, Altman DG. Survival analysis part I: basic concepts and first analyses. Br J Cancer. 2003;89:232–8.
   PubMed Web of Science ®Google Scholar
• Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res. 2015;27:1785–805.
   Google Scholar
• Raket LL. Statistical disease progression modeling in Alzheimer Disease. Front Big Data. 2020;3:24.
   PubMedGoogle Scholar
• Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.
   PubMed Web of Science ®Google Scholar
• Cao W, Fan D. Neutrophils: a subgroup of neglected immune cells in ALS. Front Immunol. 2023;14:1246768.
   PubMed Web of Science ®Google Scholar
• Cui C, Ingre C, Yin L, Li X, Andersson J, Seitz C, et al. Correlation between leukocyte phenotypes and prognosis of amyotrophic lateral sclerosis. Elife 2022;11. doi: 10.7554/eLife.74065.
   Web of Science ®Google Scholar
• Grassano M, Manera U, De Marchi F, Cugnasco P, Matteoni E, Daviddi M, et al. The role of peripheral immunity in ALS: a population-based study. Ann Clin Transl Neurol. 2023;10:1623–32.
   PubMed Web of Science ®Google Scholar
• Murdock BJ, Bender DE, Kashlan SR, Figueroa-Romero C, Backus C, Callaghan BC, et al. Increased ratio of circulating neutrophils to monocytes in amyotrophic lateral sclerosis. Neurol Neuroimmunol Neuroinflamm. 2016;3:e242–e.
   PubMed Web of Science ®Google Scholar
• Santos KF, Azevedo RM, Costa CCPd, Bento DCP, Reis AAdS, Santos RS. Neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) as neuroinflammatory biomarkers in amyotrophic lateral sclerosis (ALS) progression. RSD. 2022;11:e29611528073.
   Google Scholar
• Yazdani S, Mariosa D, Hammar N, Andersson J, Ingre C, Walldius G, et al. Peripheral immune biomarkers and neurodegenerative diseases: a prospective cohort study with 20 years of follow‐up. Ann Neurol. 2019;86:913–26.
   PubMed Web of Science ®Google Scholar
• Arbel Y, Finkelstein A, Halkin A, Birati EY, Revivo M, Zuzut M, et al. Neutrophil/lymphocyte ratio is related to the severity of coronary artery disease and clinical outcome in patients undergoing angiography. Atherosclerosis 2012;225:456–60.
   PubMed Web of Science ®Google Scholar
• Froom P, Shimoni Z. Prediction of hospital mortality rates by admission laboratory tests. Clin Chem. 2006;52:325–8.
   PubMed Web of Science ®Google Scholar
• Nahm FS. Receiver operating characteristic curve: overview and practical use for clinicians. Korean J Anesthesiol. 2022;75:25–36.
   PubMed Web of Science ®Google Scholar
• Murdock BJ, Zhou T, Kashlan SR, Little RJ, Goutman SA, Feldman EL. Correlation of peripheral immunity with rapid amyotrophic lateral sclerosis progression. JAMA Neurol. 2017;74:1446–54.
   PubMed Web of Science ®Google Scholar
• Beers DR, Henkel JS, Zhao W, Wang J, Appel SH. CD4+ T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS. Proc Natl Acad Sci U S A. 2008;105:15558–63.
   PubMed Web of Science ®Google Scholar
• Garbuzova-Davis S, Sanberg PR. Blood-CNS Barrier Impairment in ALS patients versus an animal model. Front Cell Neurosci. 2014;8:21.
   PubMed Web of Science ®Google Scholar
• Thonhoff JR, Simpson EP, Appel SH. Neuroinflammatory mechanisms in amyotrophic lateral sclerosis pathogenesis. Curr Opin Neurol. 2018;31:635–9.
   PubMed Web of Science ®Google Scholar
• Figueroa-Romero C, Monteagudo A, Murdock BJ, Famie JP, Webber-Davis IF, Piecuch CE, et al. Tofacitinib suppresses natural killer cells in vitro and in vivo: implications for amyotrophic lateral sclerosis. Front Immunol. 2022;13:773288.
   PubMed Web of Science ®Google Scholar
• Kwon HS, Koh S-H. Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes. Transl Neurodegener. 2020;9:42.
   PubMed Web of Science ®Google Scholar
• Butterfield TA, Best TM, Merrick MA. The dual roles of neutrophils and macrophages in inflammation: a critical balance between tissue damage and repair. J Athl Train. 2006;41:457–65.
   PubMed Web of Science ®Google Scholar
• Kurimoto T, Yin Y, Habboub G, Gilbert HY, Li Y, Nakao S, et al. Neutrophils express oncomodulin and promote optic nerve regeneration. J Neurosci. 2013;33:14816–24.
   PubMed Web of Science ®Google Scholar
• McGill RB, Steyn FJ, Ngo ST, Thorpe KA, Heggie S, Ruitenberg MJ, et al. Monocytes and neutrophils are associated with clinical features in amyotrophic lateral sclerosis. Brain Commun. 2020;2:fcaa013.
   PubMedGoogle Scholar
• Rashid Chehreh Bargh S, Tafakhori A, Masoumi F, Rahmani F, Ahmadi M, Namdar A, et al. Evaluation of regulatory T lymphocytes and IL2Ra and FOXP3 gene expression in peripheral mononuclear cells from patients with amyotrophic lateral sclerosis. Ir J Med Sci. 2018;187:1065–71.
   PubMed Web of Science ®Google Scholar
• Sheean RK, McKay FC, Cretney E, Bye CR, Perera ND, Tomas D, et al. Association of regulatory T-cell expansion with progression of amyotrophic lateral sclerosis: a study of humans and a transgenic mouse model. JAMA Neurol. 2018;75:681–9.
   PubMed Web of Science ®Google Scholar
• Beers DR, Henkel JS, Zhao W, Wang J, Huang A, Wen S, et al. Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis. Brain. 2011;134:1293–314.
   PubMed Web of Science ®Google Scholar
• Jin M, Günther R, Akgün K, Hermann A, Ziemssen T. Peripheral proinflammatory Th1/Th17 immune cell shift is linked to disease severity in amyotrophic lateral sclerosis. Sci Rep. 2020;10:5941.
   PubMed Web of Science ®Google Scholar
• Baykan H, Baykan O, Esen EC, Tirak A, Gorgulu SA, Karlidere T. Neutrophil-to-lymphocyte ratio as a potential differential diagnostic marker for Alzheimer’s disease, major depressive disorder, and Parkinson’s disease. Düşünen Adam (Bakırköy Ruh ve Sinir Hastalıkları Hastanesi) 2018;31:389–95.
   Google Scholar
• Zhang L, Cao B, Hou Y, Wei Q, Ou R, Zhao B, et al. High neutrophil-to-lymphocyte ratio predicts short survival in multiple system atrophy. NPJ Parkinsons Dis. 2022;8:11.
   PubMed Web of Science ®Google Scholar
• Inci I, Kusbeci OY, Eskut N. The neutrophil-to-lymphocyte ratio as a marker of peripheral inflammation in progressive supranuclear palsy: a retrospective study. Neurol Sci. 2020;41:1233–7.
   PubMed Web of Science ®Google Scholar
• Bilen MA, Rini BI, Voss MH, Larkin J, Haanen J, Albiges L, et al. Association of neutrophil-to-lymphocyte ratio with efficacy of first-line avelumab plus axitinib vs. sunitinib in patients with advanced renal cell carcinoma enrolled in the phase 3 JAVELIN renal 101 trial. Clin Cancer Res. 2022;28:738–47.
   PubMed Web of Science ®Google Scholar
• Contaldi E, Magistrelli L, Cosentino M, Marino F, Comi C. Lymphocyte count and neutrophil-to-lymphocyte ratio are associated with mild cognitive impairment in Parkinson’s disease: a single-center longitudinal study. J Clin Med 2022;11:5543.
   PubMed Web of Science ®Google Scholar
• Kara SP, Altunan B, Unal A. Investigation of the peripheral inflammation (neutrophil-lymphocyte ratio) in two neurodegenerative diseases of the central nervous system. Neurol Sci. 2022;43:1799–807.
   PubMed Web of Science ®Google Scholar
• Muñoz‐Delgado L, Macías‐García D, Jesús S, Martín‐Rodríguez JF, Labrador‐Espinosa MÁ, Jiménez‐Jaraba MV, et al. Peripheral immune profile and neutrophil‐to‐lymphocyte ratio in Parkinson’s disease. Mov Disord. 2021;36:2426–30.
   PubMedGoogle Scholar
• Sayed AA, Allam AA, Sayed AI, Alraey MA, Joseph MV. The use of neutrophil-to-lymphocyte ratio (NLR) as a marker for COVID-19 infection in Saudi Arabia: a case-control retrospective multicenter study. Saudi Med J. 2021;42:370–6.
   PubMed Web of Science ®Google Scholar